Hims & Hers Health (NYSE:HIMS) Given New $24.00 Price Target at Piper Sandler

Hims & Hers Health (NYSE:HIMS) had its target price raised by Piper Sandler from $21.00 to $24.00 in a report released on Monday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities research analysts have also recently issued reports on HIMS. TD Cowen reissued a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Morgan Stanley began coverage on Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price objective for the company. Needham & Company LLC lifted their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $24.80.

Hims & Hers Health Trading Down 7.0 %

Shares of NYSE HIMS opened at $25.74 on Monday. The stock has a market cap of $5.62 billion, a P/E ratio of 58.50 and a beta of 1.31. The business’s fifty day simple moving average is $26.97 and its 200-day simple moving average is $21.59. Hims & Hers Health has a 12-month low of $8.14 and a 12-month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the business earned ($0.04) EPS. The firm’s revenue was up 77.1% compared to the same quarter last year. On average, equities analysts forecast that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares in the company, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction on Monday, October 14th. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the transaction, the chief financial officer now directly owns 145,763 shares of the company’s stock, valued at approximately $2,960,446.53. This represents a 64.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,333,446 shares of company stock valued at $34,175,197 in the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after purchasing an additional 2,152 shares during the last quarter. Quest Partners LLC grew its stake in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares during the last quarter. CWM LLC increased its position in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp bought a new stake in Hims & Hers Health in the second quarter valued at $111,000. Finally, Quarry LP boosted its holdings in shares of Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after acquiring an additional 2,913 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.